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 2 
Abstract 3 
Study of virus entry into host cells is important for understanding viral tropism and 4 
pathogenesis. Studying the entry of in vitro cultured viruses is not always practicable. Study 5 
of highly pathogenic viruses, viruses that do not grow in culture, and viruses that rapidly 6 
change phenotype in vitro can all benefit from alternative models of entry.  Retrovirus 7 
particles can be engineered to display the envelope proteins of heterologous enveloped 8 
viruses. This approach, broadly termed ‘pseudotyping’, is an important technique for 9 
interrogating virus entry. In this perspective we consider how retrovirus pseudotypes have 10 
addressed these challenges and improved our understanding of the entry pathways of 11 
diverse virus species, including Ebolavirus, human immunodeficiency virus and hepatitis C 12 
virus. 13 
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Executive Summary 19 
 The entry of a virion into a host cell is an essential step in viral life cycles. As such, entry is a 20 
potential target for clinical intervention. Viral entry pathways are also the target for 21 
neutralizing antibodies generated by immunization with vaccines possessing virion 22 
components. 23 
 Enveloped viruses cause a range of diseases in humans and animals, from acute infections 24 
such as Ebola and Influenza, to chronic infections such as hepatitis B virus, hepatitis C virus 25 
and human immunodeficiency virus. The entry pathways of these enveloped viruses are 26 
complex and vary between virus species. Greater understanding of the steps of cell binding, 27 
internalisation and fusion are important for designing novel therapies for virus infections. 28 
 The ability to experimentally generate retroviruses pseudotyped with heterologous 29 
envelope proteins provides a flexible platform for investigating the entry pathways of a wide 30 
range of genetically diverse viruses. While culture models exist for some viruses that permit 31 
investigation of entry there are examples of viruses where investigating entry in isolation is 32 
beneficial. 33 
 Entry of highly pathogenic viruses such as Ebolavirus and Rabies virus can be studied using 34 
retroviral pseudotypes as a surrogate entry model, without the safety concerns associated 35 
with working with full-length infectious viral genomes 36 
 In vitro culture of viruses with RNA genomes can lead to culture-associated adaptation and 37 
perturbation of the phenotype of the virus. The use of retroviral pseudotypes to study the 38 
entry pathways of these viruses can address this problem, using high-fidelity PCR to 39 
generate accurate representations of the envelope protein sequences from clinical 40 
specimens. 41 
 Retroviral pseudotypes can be used to study the entry pathways of viruses that do not 42 
readily replicate in culture, such as hepatitis C virus. 43 
 For those viruses that encode proteins in different overlapping open reading frames, the use 44 
of retroviral pseudotypes can facilitate specific investigation of the entry phenotype of 45 
mutants in isolation from the effects of coding changes in other virus-encoded proteins. 46 
 Retroviral pseudotypes can also be used to identify host factors that act as restriction factors 47 
that act on the entry pathways of diverse viral species. 48 
 49 
 50 
  51 
Introduction 52 
Viruses possessing host-derived envelope membranes make up a large number of viral 53 
human pathogens, including members of the positive-stranded and negative stranded RNA 54 
viruses. The on-going challenges of global eradication of chronic virus infections such as 55 
human immunodeficiency virus 1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV) 56 
demonstrate that new therapeutic approaches are required for these infections. In addition, 57 
recent zoonotic outbreaks such as new influenza virus variants, Ebola virus and Zika virus 58 
have highlighted the need for improved surveillance and greater understanding of the 59 
pathogenicity of emerging viruses.  Enveloped viruses important to human health are 60 
genetically diverse, for example members of the families Flaviviridae, Retroviridae, 61 
Filoviridae, Arenaviridae, Orthomyxoviridae and Coronaviridae. These virus families have 62 
distinct replication strategies and present unique challenges for therapy. However, 63 
expression of a virus-encoded trans-membrane protein that mediates the entry process is a 64 
common feature of all these virus species. As such, greater understanding of these distinct 65 
entry pathways may inform development of novel interventions for virus infections.  66 
Entry pathways of enveloped viruses 67 
Understanding virus entry pathways is important for determining host range and tissue 68 
specificity of different virus infections. Enveloped viruses gain entry to a host cell by one of 69 
two main mechanisms, both of which require attachment of a virus particle to host-encoded 70 
receptors on the plasma membrane (reviewed in [1]).  Viruses can utilise the host 71 
endocytosis pathway to internalise particles into endosomes, leading to pH-dependent 72 
fusion of the viral envelope with the host cell membrane in early endosomes (e.g. Nipah 73 
virus [2]) or at lower pH after endosome fusion with lysosomes (e.g. Dengue virus [3]). 74 
Alternatively, viral fusion and entry can take place at the cell surface in a pH-independent 75 
manner, with receptor engagement triggering membrane rearrangement to result in 76 
internalisation of the viral nucleocapsid at the plasma membrane. HIV-1 has long been cited 77 
as an example of pH-independent plasma membrane fusion [4, 5]. More recent analyses 78 
have demonstrated that HIV-1 fusion occurs in endosomes [6], although this has been 79 
disputed [7]. Irrespective of the mechanism of entry, virus-encoded membrane-spanning 80 
proteins mediate these receptor binding and membrane fusion events, resulting in 81 
internalisation of the capsid into the cell cytoplasm. As such, the envelope proteins are the 82 
main target of neutralizing antibodies, which block receptor interactions and aggregate virus 83 
particles. In addition, envelope proteins are often highly glycosylated, which may help 84 
protect the virus from host immune recognition [8]. Intimate knowledge of entry pathways 85 
can inform development of new therapies for virus infections, and has already led to the 86 
development of clinically approved drugs targeting entry of HIV-1 [9] and respiratory 87 
syncytial virus (RSV) [10].  88 
It is important to note that the entry pathways of non-enveloped viruses is fundamentally 89 
different to that of enveloped viruses. Entry of these viruses does not involve membrane 90 
fusion and requires penetration of the virus particle through a host cell membrane 91 
(reviewed in [11]). This penetration is mediated by the virus’ outer capsid antigens, which 92 
typically form highly ordered, symmetrical structures that contribute to virion structure. A 93 
good example of this is the Bluetongue virus (BTV) particle, which is formed of concentric 94 
layers of VP3, VP7 and VP5, with the outer-most virus protein VP2 embedded into this 95 
layered structure [12]. The surface proteins of enveloped and non-enveloped viruses may 96 
share some biochemical characteristics, but the characteristic trans-membrane domain of 97 
enveloped-virus surface proteins is lacking in these viruses.  98 
While laboratory investigation of the entry pathways of many viruses can be performed 99 
using cultured virus isolates, there are situations where this is not desirable: 1) Highly 100 
pathogenic viruses that require high level containment facilities; 2) Viruses that rapidly 101 
accumulate mutations and culture adaptations, and where investigation of accurate 102 
representations of virus populations is important; 3) Viruses that do not readily grow in 103 
culture, or where host restriction in cultured cells occurs at a post-entry step; 4)  Viruses for 104 
which molecular clones are not available, or where reverse-genetics approaches are desired 105 
to manipulate the glycoproteins to investigate molecular determinants of entry pathways. 106 
This latter group includes viruses with overlapping reading frames, where mutations in the 107 
envelope proteins results in additional amino acid substitutions in other viral proteins. One 108 
possible approach to overcome the limitations of virus culture is the use of chimeric viruses. 109 
Because the envelope proteins are necessary and sufficient for entry, it is possible to study 110 
entry pathways using experimental models that reconstitute only the viral envelope protein 111 
binding to cell surfaces. This has led to the development of a range of experimental models 112 
with which to study viral tropism and entry, including infection with virus-like particles [13, 113 
14], infectious pseudotypes [15-17], protein binding assays [18, 19] and liposome fusion 114 
assays [20, 21]. These models also facilitate assessment of inhibitors that specifically target 115 
viral entry pathways in isolation from other steps of the replication cycle [22, 23]. 116 
 117 
Retrovirus-based pseudotypes  118 
Retroviruses are excellent platforms for creating chimeric virus particles with which to 119 
investigate viral entry. In contrast to many viruses, retroviruses are able to incorporate 120 
foreign proteins into their envelope membrane, including host-derived proteins and 121 
envelope proteins of other viruses [24-29]. This promiscuous protein incorporation naturally 122 
results in phenotype mixing in cells infected with different species of retrovirus [30, 31]. The 123 
wide range of viral surface proteins that have been successfully incorporated into 124 
retroviruses has recently been reviewed [32]. Following infection retroviruses deliver and 125 
integrate a DNA copy of their RNA genome into the host genome of an infected cell during 126 
replication. This facilitates introduction of reporter genes into retroviral genomes along with 127 
strong promoters, resulting in expression of the integrated reporter genes. This permits 128 
design of rapid, sensitive quantitative infection assays that can be easily re-purposed for 129 
studying the entry of a range of enveloped viruses (Figure 1).  It should be noted that while 130 
we consider only retrovirus pseudotypes in this Perspective, heterologous viral 131 
glycoproteins have been successfully pseudotyped onto vesicular stomatitis virus (VSV) 132 
particles [33]. VSV pseudotypes, along with approaches using enveloped virus-like particles 133 
(VLPs) [34] have also made a significant contribution to our understanding of viral entry 134 
pathways. These experimental models are restricted to studying the surface proteins of 135 
enveloped viruses, as the surface capsid proteins of nonenveloped viruses cannot be readily 136 
incorporated into the chimeric retrovirus particles as they lack a trans-membrane domain. 137 
Retroviral pseudotyping provides an experimental model to investigate the early stages of 138 
entry of enveloped viruses without introducing sequence adaptations associated with in 139 
vitro culture and passage of viruses. In addition, this experimental system provides a robust 140 
model with which to rapidly investigate the phenotype of envelope proteins representing 141 
diverse viral variants. It is important to distinguish between pseudotypes generated with the 142 
two main groups of retrovirus packaging constructs: lentiviruses and gammaretroviruses.  143 
Pseudotypes based on lentiviruses such HIV-1 and simian immunodeficiency virus (SIV) are 144 
able to infect and integrate into terminally-differentiated cells.  In contrast, those based on 145 
gammaretroviruses such as murine leukaemia virus (MLV) and gibbon ape leukaemia virus 146 
(GALV) generally require nuclear membrane degradation during mitosis to deliver and 147 
integrate their genome into that of the host cell, limiting investigations of virus entry 148 
pathways to actively dividing cells [35]. However, pseudotypes of the gammaretrovirus 149 
Friend MLV (F-MLV) may transduce non-dividing cells under certain conditions [36]. Despite 150 
these differences both HIV-1 and MLV have been popular choices for pseudotype virus 151 
production, with optimised protocols for both species [37, 38].  152 
Retroviral pseudotyping was originally applied to investigations into retrovirus entry using 153 
surface proteins encoded by the env gene (surface glycoprotein; SU and transmembrane 154 
protein; TM) [25, 27]. These retroviruses were also found to incorporate heterologous viral 155 
surface proteins [28, 39], permitting analysis of a wide range of variants [24]. Glycoproteins 156 
recovered from a range of retrovirus species have been pseudotyped onto heterotypic 157 
retrovirus backbones, including gammaretroviruses (ecotropic and amphotropic MLV and 158 
GALV), and lentiviruses. These studies revealed that different retrovirus species can possess 159 
pH-dependent or pH-independent entry pathways [40, 41], suggesting that different 160 
retroviruses use distinct entry pathways. 161 
The methodological approaches for the generating retroviral pseudotypes for studies of 162 
virus entry have been described and reviewed many times [42-44]. Here we discuss how 163 
retrovirus pseudotypes have contributed to the understanding of receptor usage, the cell 164 
biology of viral entry, and the consequences of genetic diversity on envelope protein 165 
function. 166 
Application of retroviral pseudotypes to investigating entry of highly pathogenic viruses  167 
Filovirus infections, including Ebolavirus, are a major cause of haemorrhagic fevers and are 168 
increasingly studied after the unprecedented 2013-16 outbreak in West Africa. The entry 169 
pathways of haemorrhagic filoviruses are important targets for intervention, with a cocktail 170 
of therapeutic antibodies (Zmapp) being successfully used to protect against infection [45]. 171 
While Ebolavirus (EBOV) and Marburg virus (MARV) have demonstrated the ability to rapidly 172 
emerge in resource-limited settings, other members of this family result in lower 173 
pathogenicity infections in humans. Their highly pathogenic nature makes investigations of 174 
Ebolaviruses restricted to containment level 4 laboratories. As such, retroviral pseudotypes 175 
provide a safe, flexible platform for investigating the entry pathways of these viruses. 176 
Filoviruses express two glycoproteins, GP1 and GP2, cleaved from a single precursor [46], 177 
which mediate receptor binding and fusion, respectively. Retroviruses pseudotyped with the 178 
EBOV/MARV glycoproteins have been used to investigate the entry pathway in great detail 179 
[15, 16].  The folate receptor α was initially proposed as a co-factor in the entry pathways of 180 
both viruses [47], but this has subsequently been queried [48]. T cell immunoglobulin and 181 
mucin domain 1 (TIM-1) was more recently identified as an entry factor for both viruses by 182 
assessing EBOV pseudotype entry in a panel of transformed cell lines with defined gene 183 
expression [49].  A similar approach identified members of the Tyro3 transmembrane 184 
tyrosine kinases (Axl, Dtk and Mer) as entry cofactors [50]. Differences in entry of EBOV and 185 
MARV were also revealed using pseudotypes. MARV pseudotype entry was resistant to 186 
glycosylation inhibitors in target cells, in contrast to the tunicamycin- and Endoglycosidase 187 
H-sensitive entry of EBOV [51]. This highlighted differences in cellular receptors for these 188 
two related viruses. Retrovirus pseudotypes have recently been applied to identifying the 189 
Niemann-Pick C1 (NPC1) protein as the major GP-binding receptor for Ebolavirus [52, 53]. 190 
They have also been used to identify molecular determinants of receptor tropism in 191 
different strains [54]. Together, these studies demonstrate that retrovirus pseudotypes are 192 
a powerful tool for investigating the receptor-mediated entry pathway of a range of 193 
filoviruses, which would otherwise require high-containment laboratories. These models 194 
have accelerated Ebolavirus research and recently assisted with defining the mode of action 195 
of antiviral antibodies that target the entry pathway [55].  196 
Rhabdovirus glycoproteins, including those of rabies virus, have been readily pseudotyped 197 
onto retrovirus backbones, including infectious equine anaemia virus and HIV-1 [56, 57]. 198 
These pseudotypes have been used to investigate the neuronal transport of virions 199 
mediated by the rabies virus glycoprotein [58]. Retrovirus pseudotypes of rabies, VSV and 200 
mokola viruses (as well as EBOV and lymphocytic choriomeningitis virus – LCMV) enabled 201 
investigation of neuronal cell tropism in vivo. Injection of these pseudotypes into the brains 202 
of mice facilitated post-mortem identification of permissive cell types by staining for the 203 
beta-galactosidase reporter enzyme packaged by the pseudotypes [59]. A similar technique 204 
has been used for skin cell tropism of VSV [60]. Furthermore, lentivirus pseudotyping of 205 
chimeric glycoproteins comprising domains of rabies G and VSV G enabled phenotyping of 206 
fusion glycoproteins possessing unique entry characteristics and neuronal cell tropism for 207 
use in retrograde transduction systems [61]. 208 
 209 
Applications with highly diverse virus populations 210 
An important use of retrovirus pseudotypes is accurate assessment of the phenotypes of 211 
envelope proteins recovered from viruses that undergo rapid mutation and selection in vivo. 212 
Passaging these viruses in cell culture can often result in rapid adaptation to culture, as the 213 
absence of the constraining environment of the natural host cell and immune responses 214 
alters the selection pressures acting on a viral quasispecies. Isolating viral envelope protein 215 
gene sequences with high-fidelity approaches allows accurate assessment of the properties 216 
of circulating variants with pseudotypes [62, 63]. Studies of HIV-1 entry provide a good 217 
example of this approach. The error-prone nature of the virus-encoded reverse 218 
transcriptase facilitates rapid adaptation in tissue culture with mutations in the envelope 219 
glycoprotein gene env resulting in phenotypic changes [64, 65]. This hindered research into 220 
HIV entry, as receptor usage of laboratory-adapted, cultured strains was inconsistent with 221 
those naturally infecting human hosts. Retroviruses pseudotyped with HIV-1 envelope 222 
glycoproteins were used to identify host receptors as determinants of entry. HIV variants 223 
have differential usage of CD4 and the chemokine receptors CXCR4 and CCR5 [66-68], and it 224 
was recently demonstrated that CD4 usage by HIV-1 pseudotypes is linked to breadth of 225 
tropism [69].  226 
HIV-1 constructs pseudotyped with envelope glycoproteins that mediate pH-independent 227 
entry were also demonstrated to be enhanced by the action of the HIV-1 nef protein, 228 
revealing a role for nef in entry [70]. The entry properties of genetically diverse HIV-1 env 229 
clones were assessed using pseudotyped virus infection of peripheral blood mononuclear 230 
cells (PBMCs) [71]. The development of rapid HIV-1 pseudotype screening assays [72] has 231 
more recently facilitated assessment of entry of genetically diverse strains of HIV-1 for 232 
studies of entry inhibition [73].  233 
Applications to viruses that do not grow in culture 234 
Study of the hepatitis C virus (HCV) entry pathway presents additional challenges to that of 235 
HIV-1, as HCV is not readily propagated in vitro. Only one strain of HCV (JFH-1) robustly 236 
replicates in tissue culture without the requirement for culture adaptations. Laboratory-237 
generated chimeric viruses based on JFH-1 rapidly accumulate in vitro adaptations [74]. The 238 
error-prone replication of HCV coupled with the persistent, chronic nature of infection 239 
results in extreme levels of diversity between isolates identified in different host 240 
backgrounds [75]. The diversity observed between different HCV genotypes far exceeds that 241 
observed for other chronic infections, such as HIV-1 [76]. HCV encodes two envelope 242 
proteins, E1 and E2, which are necessary and sufficient for mediating entry of the virus. 243 
However, these genes are able to tolerate extreme genetic diversity (reviewed in [75]), and 244 
are common sites of in vitro culture adaptations. Nucleotide sequence variation approaches 245 
40% between individual viruses. Early studies of the entry pathway of HCV were severely 246 
limited by the lack of robust cell culture models in transformed hepatoma cultures. The 247 
introduction of retroviruses pseudotyped with the HCV E1 and E2 proteins (hepatitis C virus 248 
pseudoparticles; HCVpp) facilitated rapid developments in our understanding of the 249 
complex receptor cascade required for HCV entry (see Figure 1) [77, 78]. These studies 250 
initially identified CD81 and SR-BI as key receptors for entry [79], and later identified tight 251 
junction proteins including claudins [80, 81] and occludin [82] as key entry factors that play 252 
a role in the entry cascade. HCVpp were also used to identify the sequential order of events 253 
in the entry cascade [83-85]. E2 is the major receptor binding protein, while E1 plays a role 254 
in chaperoning the folding of the E2 protein and contributes to envelope membrane fusion 255 
[86]. HCVpp were used to map the interactions between these glycoproteins and receptors 256 
to the amino acid level by studies using panels of individual point-mutation variants in 257 
controlled genetic backgrounds [87-90]. The fusion mechanism for HCV is yet to be 258 
completely resolved, but studies have located elements in both the E1 and E2 proteins that 259 
contribute to fusion [86, 91]. More recently, mutations that affect the pH-dependent nature 260 
of HCV entry have been tested using pseudotypes, implicating the hypervariable 1 (HVR-1) 261 
in pH-dependent fusion [92].  262 
HCV tissue tropism has been investigated with HCVpp. These particles have been found to 263 
enter neuroblastoma cell lines [93] and neuroepithelioma cells [94]. Pseudotypes were also 264 
used to analyse the contribution of kinases in the HCV entry pathway [95], the process of 265 
endocytosis in the entry cascade [96] and the importance of cell polarity in HCV receptor 266 
association [97]. The discovery that human serum enhances infection of HCVpp into 267 
hepatocytes led to investigations of lipoprotein-mediated HCV infection. High-density 268 
lipoprotein (HDL) was discovered to enhance infection by accelerating endocytosis [98], 269 
through interactions with the SR-BI receptor [99] and the HVR-1 region of the HCV E2 270 
glycoprotein [100].  271 
The use of HCVpp to interrogate the properties of genetically diverse viral isolates has 272 
revealed that while all genotypes of HCV use conserved entry pathways [101], entry 273 
phenotypes vary considerably between isolates [102, 103]. Closely related members of an 274 
individual quasispecies can have significantly different entry efficiencies into host cells [38, 275 
104]. These entry assays revealed different phenotypes of variants that are preferentially 276 
transmitted between hosts [63]. By comparing E1/E2 nucleotide sequences of genetically 277 
diverse functional HCVpp, discontinuous conserved receptor binding regions were proposed 278 
[87]. Interrogation of these regions with point mutations identified critical residues involved 279 
in the interaction with CD81. The success of this approach was revealed when core crystal 280 
structures of the E2 protein became available [105, 106], confirming the discontinuous 281 
nature of the conserved amino acids constituting the CD81 binding site. 282 
Application to viruses with overlapping reading frames. 283 
The hepatitis B virus (HBV) life cycle has been studied in detail. However, the entry cascade 284 
has only recently been characterised at a molecular level [107]. HBV possesses a variable 285 
genome, with 8-10% difference observed on the nucleotide level between strains. HBV is 286 
categorised into at least 8 distinct genetic types, which differ in geographic distribution and 287 
pathogenicity [108]. The HBV envelope protein (HBV surface antigen - HBsAg) is expressed 288 
in three forms, with a common C-terminus but three separate initiation sites that encode 289 
the large (L), medium (M) and small (S) forms of the protein. The major sites of variability 290 
are in the surface antigen, particularly the antigenic region present in an external loop near 291 
the C-terminus. This provides the first challenge to investigating HBV entry, as culture 292 
models for rapidly assessing the phenotype of naturally occurring variants are not available 293 
[109]. In addition, the HBV genome possesses overlapping coding regions in all three 294 
translation frames. Mutations in the surface antigen can simultaneously introduce 295 
important mutations in the viral polymerase. As such, it is difficult to individually phenotype 296 
the properties of HBsAg variation in cell culture models. Retrovirus pseudotypes facilitated 297 
investigation of the HBV entry pathway [110, 111]. Initial studies identified that HBV 298 
infected primary human hepatocytes, but not hepatoma cell lines [110, 111], and illustrated 299 
the advantages of using lentivirus constructs for studies in terminally differentiated primary 300 
cells [110]. These studies also investigated the contributions of the large and small forms of 301 
the HBsAg in entry. With the discovery of the sodium taurocholate co-transporting 302 
polypeptide (NTCP) as a major entry factor [112] the models of HBV entry have rapidly 303 
advanced. Retroviruses pseudotyped with the HBsAg have recently been used to interrogate 304 
the steps in NTCP-mediated HBV entry [17], mapping NTCP binding sites to the N-terminus 305 
of the large surface antigen. 306 
Application to identifying restriction factors 307 
Retrovirus pseudotypes have been extensively employed for serology screening and analysis 308 
of neutralising antibodies [32]. They have also been important for the investigation of host 309 
cell restriction factors, such as interferon-induced transmembrane proteins (IFITMs). IFITM 310 
proteins were originally identified during siRNA screening for inhibitors of highly-pathogenic 311 
avian influenza A virus (IAV) replication. However, IFITMs have also been shown to restrict a 312 
range of viruses at a replication-independent stage using retrovirus pseudotypes [113-115]. 313 
Transduction efficiency of pseudotypes bearing the glycoproteins of filo-, corona-, flavi-, 314 
rhabdo- or orthomyxo-viruses were shown to be variously inhibited at an entry or 315 
membrane-fusion stage by different IFITM proteins. Upregulation of homologous or 316 
orthologous IFITM isoforms using lentivirus transduction demonstrated the likelihood of a 317 
shared entry pathway or feature by these enveloped RNA viruses. Retrovirus pseudotyping 318 
is uniquely suited allow scrutiny of virus entry in isolation from replication enabling the 319 
rapid and direct comparative analysis of how this restriction mechanism effects different 320 
viruses.  321 
Limitations to using retroviral pseudotypes. 322 
While retroviral pseudotypes have proven to be a valuable tool to interrogate the entry 323 
pathways of a wide range of virus species, there are potential problems that must be taken 324 
into consideration when using this experimental model. The glycoproteins of some virus 325 
species are refractive to incorporation into functional retrovirus pseudotypes, leading to 326 
undetectable infection, even when using sensitive reporter assays (unpublished data). Even 327 
where viral envelope proteins can be successfully pseudotyped, single amino acid 328 
substitutions in the viral glycoprotein can have an impact on the conditions required to 329 
generate infectious particles [38]. Attempts to pseudotype flaviviruses such as West Nile 330 
virus (WNV) and Zika virus have proven difficult, despite related viruses such as HCV being 331 
amenable to pseudotype manufacture. This may be linked to the structural role of the 332 
envelope glycoproteins in virus species of the genera such as Flavivirus, while the 333 
glycoproteins of hepaciviruses such as HCV do not appear to play such a structural role in 334 
virions [116].   335 
Envelope glycoproteins can display different phenotypes when present on a retrovirus 336 
envelope rather than their natural virion. The neutralization phenotype of HIV-1 strains 337 
differs between primary virus isolates and their pseudotyped equivalents [73]. Point 338 
mutations in the HCV E1/E2 genes do not always result in the same phenotype when 339 
pseudotypes are compared to cell-cultured virus [90, 117]. Also, due to the nature of the 340 
producer cell lines, some post-translational modifications might not be accurately modelled 341 
by pseudotypes. An example of this is the complex of apolipoproteins that form when HCV 342 
is assembled in hepatocytes. Without producing the pseudotyped viruses in hepatocytes 343 
these essential modifications, particularly incorporation of Apolipoprotein E, do not occur 344 
[118, 119]. This could generate misleading data, especially if these virion components 345 
impact on the entry pathway of the virus. 346 
When preparing pseudotype entry assays for analysing virus entry pathways, it is important 347 
to optimise the assay for the envelope protein being tested (reviewed in [44]). Variables 348 
such as the type and source of producer cells, the amount and type of plasmids required to 349 
generate infectious particles, and the reporter gene all influence the outcome of infection 350 
experiments. Of particular importance is the selection of packaging plasmids. Differences in 351 
the assembly of murine leukemia virus and human immunodeficiency virus appear to 352 
influence incorporation of heterologous viral envelope proteins, and can determine if 353 
infection is successful [38]. The selection of appropriate target cells expressing necessary 354 
virus entry molecules also influences the ability to assay infection [78].  Together these 355 
considerations can impose practical limitations on assay setup, as glycoproteins from 356 
different virus species can behave very differently in these assays. Protocols for generation 357 
of particles can impact on the function of the expressed particles, with small changes being 358 
sufficient to alter function of a pseudotyped envelope protein [38].  359 
Finally, there have been concerns about potential contamination of cell lines used for these 360 
experiments with ecotropic retroviruses, which may affect results of infectivity assays with 361 
pseudotyped retroviruses. However, at least for HIV-1 infection assays, it has been 362 
demonstrated that these contaminants do not affect the results of infection assays [120]. 363 
Future applications for retroviral pseudotypes 364 
Pseudotypes have proven to be a robust experimental system to investigate the entry 365 
pathways of a wide range of genetically diverse virus species. The current interest in the 366 
potential for emerging (and re-emerging) viral pathogens means that retroviral pseudotypes 367 
could be deployed rapidly to identify receptor usage and tropism of newly-discovered 368 
pathogens. In addition, there is still plenty to learn about the entry pathways of established 369 
viral pathogens such as HCV and HBV. Retroviral pseudotypes will continue to be an 370 
essential experimental model for these studies. 371 
As viral entry has been highlighted as a potential target for clinical intervention in a wide 372 
variety of virus infections, the development of broadly-active inhibitors using these entry 373 
models may contribute to preparedness for viral epidemics. Retroviral pseudotypes 374 
facilitate high-throughput entry inhibitor screening without the requirement to understand 375 
the complexities of entry of a specific virus species. Characterising the interactions between 376 
entry inhibitors (such as neutralizing antibodies) and viral envelope proteins will also 377 
provide useful tools for investigating the molecular biology of virus entry. 378 
Retroviral pseudotypes have contributed to our knowledge of the entry pathways of a wide 379 
range of viruses. In addition to the examples given here, there are many studies of virus 380 
entry that utilise this model, including those of coronaviruses and Influenza viruses. While 381 
this Perspective article cannot hope to exhaustively cover each application, we hope that 382 
the examples provided here illustrate the versatility of pseudotypes as models of virus 383 
entry. 384 
 385 
Figures 386 
Figure 1. Generation of retroviruses pseudotyped with heterologous viral envelope 387 
proteins. A) In second-generation pseudotype models, retroviral pseudotypes are produced 388 
using genes encoded on three separate plasmids; a packaging vector possessing the entire 389 
retroviral gag/pol open reading frame of a specific retrovirus (usually HIV-1 or MLV; blue), a 390 
reporter vector possessing a reporter gene (usually either luciferase, green fluorescent 391 
protein, or β-galactosidase; green), the 3’ and 5’ LTRs of a retrovirus matched to the 392 
packaging vector, along with a strong promoter and a retrovirus packaging signal (ψ); and a 393 
plasmid encoding the glycoprotein(s) of a heterologous virus of interest (yellow/orange). 394 
When transfected together into a suitable producer cell line (such as the human embryonic 395 
kidney cell line 293T), protein over-expression is driven by the strong CMV immediate-early 396 
promoter upstream of each gene. Retroviral particles are produced possessing the desired 397 
viral glycoprotein, and are released from the transfected cells into the surrounding media. 398 
B) In this way the envelope protein-encoding plasmid can be exchanged to produce particles 399 
mimicking different virus species.  400 
Figure 2. Retrovirus pseudotypes can be used to reveal many aspects of a virus entry 401 
cascade. The entry pathway of hepatitis C virus provides an excellent example of how 402 
retroviral pseudotypes can be used to dissect the complex series of events that result in 403 
internalisation of a virus into a host cell. 1. Studies utilising retrovirus pseudotypes were 404 
used to identify essential molecular interactions between viral proteins and host cell 405 
receptors. CD81 and SR-B1 were identified as key receptors that initiate early events in the 406 
entry cascade [79]. 2. The dynamic nature of interactions between receptor complexes can 407 
also be investigated. For HCV, tight junction proteins were identified as co-factors for entry, 408 
interacting dynamically with CD81 to traffic virus particles from the cell’s apical surface to 409 
tight junctions [80, 81, 85]. 3.   Species-specific receptors can be identified. Another tight 410 
junction protein, occludin, was found to be species-specific requirement for HCV entry [82].  411 
4. Pseudotypes can reveal the sequence of events that result in entry of the virus genome 412 
into the cell. HCV binding and entry involves sequential recruitment of host cell co-factors  413 
[83]. 5. Host factors other than viral receptors can contribute to virus entry. For HCV, 414 
interaction between high density lipoprotein (HDL) and the SR-B1 receptor enhances 415 
infectivity [98-100]. 6. Specific events leading to fusion of virus envelope and host 416 
membrane can be interrogated. pH-dependent membrane fusion was found to be mediated 417 
by specific regions of the HCV glycoproteins using retroviral pseudotype models [91]. 7. In 418 
addition, specific conserved amino acids were found to be involved in E1-E2 interactions and 419 
receptor binding events [87, 88]. 420 
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